All posts by Matt Rigney

According a new report from Spherix Global Insights, biologic treatment of nr-axSpA is complicated by multiple factors resulting in a significantly lower percentage of patients with nr-axSpA being treated compared to those with AS Download Report Overview EXTON, Pa., Aug….

The Q2 edition of RealTime Dynamix™: Multiple Sclerosis finds that trial rates for Ocrevus are in-line with pre-launch estimates and robust uptake of the drug is anticipated in the next six months Download Report Overview July 19, 2017 – Exton,…

According to the latest quarterly update from Spherix Global Insights, US gastroenterologists are gearing up for near term change Download Report Overview EXTON, Pa., July 7, 2017 /PRNewswire/ — Results from a recent study just released by Spherix Global Insights…

Approval of Orencia for Psoriatic Arthritis (PsA) opens door for expansion of use based on existing off-label experience, adding further challenge to Novartis’s Cosentyx and Janssen’s Stelara for preferred TNF alternative, according to recent reports from Spherix Global Insights. Download…

Not only has Stelara’s user-base substantially increased since Q1, but US gastroenterologists (n=103) are projecting significant gains for the IL-12/23 inhibitor over the next six months. Download Report Overview EXTON, Pa., June 27, 2017 /PRNewswire/ — Spherix Global Insights has…

While AbbVie’s Humira and Amgen’s Enbrel have borne the brunt of the IL-17 assault, Janssen’s Stelara has been buffered thus far. However, future projections indicate a flattening of the brand and further penetration of the IL-17 class, according to a…